Amylyx Pharmaceuticals, Inc. financial data

Symbol
AMLX on Nasdaq
Industry
Pharmaceutical Preparations
Location
43 Thorndike Street, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 565 % -19.6%
Quick Ratio 44.6 %
Debt-to-equity 20.6 % +19.6%
Return On Equity -46.2 % -93.9%
Return On Assets -38.3 % -88.5%
Operating Margin -59.5 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 68.1M shares +1.05%
Common Stock, Shares, Outstanding 68.1M shares +1.08%
Entity Public Float 1.31B USD +66.2%
Common Stock, Value, Issued 7K USD 0%
Weighted Average Number of Shares Outstanding, Basic 68M shares +1.18%
Weighted Average Number of Shares Outstanding, Diluted 68M shares -3%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 345K USD +21.1%
Revenue from Contract with Customer, Excluding Assessed Tax 299M USD -101%
Research and Development Expense 135M USD +33.6%
General and Administrative Expense 30M USD +292%
Costs and Expenses 477M USD +74.6%
Operating Income (Loss) -178M USD -119%
Nonoperating Income (Expense) 15.4M USD +46.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -162M USD -130%
Income Tax Expense (Benefit) 5.44M USD +1087%
Net Income (Loss) Attributable to Parent -166M USD -128%
Earnings Per Share, Basic -2.44 USD/shares -107%
Earnings Per Share, Diluted -2.45 USD/shares -104%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 75M USD -69.7%
Accounts Receivable, after Allowance for Credit Loss, Current 4.09M USD -87.8%
Inventory, Net 38.3M USD +292%
Assets, Current 327M USD -23.6%
Property, Plant and Equipment, Net 1.47M USD -44.1%
Operating Lease, Right-of-Use Asset 2.77M USD -40.4%
Other Assets, Noncurrent 479K USD +2.79%
Assets 332M USD -26.8%
Accounts Payable, Current 4.96M USD -79.9%
Employee-related Liabilities, Current 15.2M USD +256%
Accrued Liabilities, Current 62.8M USD +68.5%
Liabilities, Current 70.1M USD +9.36%
Operating Lease, Liability, Noncurrent 772K USD -75.4%
Liabilities 70.9M USD +5.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -97K USD -34.7%
Retained Earnings (Accumulated Deficit) -496M USD -50.2%
Stockholders' Equity Attributable to Parent 261M USD -32.4%
Liabilities and Equity 332M USD -26.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -489K USD +90.4%
Net Cash Provided by (Used in) Financing Activities 131K USD -87.4%
Net Cash Provided by (Used in) Investing Activities 819K USD -98.5%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 68.1M shares +1.08%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 351K USD -99.3%
Deferred Tax Assets, Valuation Allowance 83.9M USD -7.36%
Deferred Tax Assets, Gross 85.5M USD -7.06%
Operating Lease, Liability 4.24M USD -32.5%
Depreciation 315K USD +54.4%
Payments to Acquire Property, Plant, and Equipment 67K USD -73.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -166M USD -128%
Lessee, Operating Lease, Liability, to be Paid 4.54M USD -34.7%
Property, Plant and Equipment, Gross 4.31M USD +36.9%
Operating Lease, Liability, Current 2.37M USD +10.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.59M USD -36%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.48M USD +2.52%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 303K USD -55.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 476K USD -70%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.21M USD +118%
Lessee, Operating Lease, Liability, to be Paid, Year Four 476K USD
Operating Lease, Payments 600K USD +500%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.55M USD +12.5%
Share-based Payment Arrangement, Expense 39.2M USD +34.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%